GlassScriptPhysician profile
Zandra R Gottman
NPI 1235529512
$5,567.83
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,254 · 2022: $1,959 · 2023: $1,704 · 2024: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,326 · Education: $29.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,325.59 |
| Education | $29.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,103.48 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $654.14 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Abbott Laboratories | $621.17 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $475.44 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $383.11 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $347.81 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $199.55 | 2023-2024 | |
| Biohaven Pharmaceuticals, INC. | $190.34 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $183.00 | 2021-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $171.55 | 2021-2022 | |
| Dexcom, INC. | $163.74 | 2021-2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $161.54 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $151.64 | 2021-2024 | |
| Amgen INC. | $103.82 | 2021-2024 | Evenity, Prolia, Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.23 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $64.73 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $53.65 | 2022-2023 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.32 | 2023-2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $50.61 | 2022-2023 | |
| Exact Sciences Corporation | $45.61 | 2023-2024 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $44.79 | 2022 | |
| Lundbeck LLC | $39.84 | 2023-2024 | Rexulti |
| Upsher-Smith Laboratories LLC | $38.01 | 2021-2022 | |
| Boston Scientific Corporation | $35.14 | 2024 | Watchman Flx |
| Phathom Pharmaceuticals, INC. | $28.46 | 2024 | Voquezna |
| Nevro Corp. | $25.62 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $23.88 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $15.62 | 2023 | Jornay Pm |
| Esperion Therapeutics, INC. | $13.89 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.14 | 2022 | |
| Amarin Pharma, INC. | $12.65 | 2022 | |
| Endogastric Solutions, INC | $7.31 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zandra Gottman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.